BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30143751)

  • 1. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
    Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
    Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.
    Jones H; Hargrove L; Kennedy L; Meng F; Graf-Eaton A; Owens J; Alpini G; Johnson C; Bernuzzi F; Demieville J; DeMorrow S; Invernizzi P; Francis H
    Hepatology; 2016 Oct; 64(4):1202-1216. PubMed ID: 27351144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2
    Kennedy L; Hargrove L; Demieville J; Karstens W; Jones H; DeMorrow S; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Smith S; Akers A; Meadows V; Francis H
    Hepatology; 2018 Sep; 68(3):1042-1056. PubMed ID: 29601088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2
    Meadows V; Kennedy L; Hargrove L; Demieville J; Meng F; Virani S; Reinhart E; Kyritsi K; Invernizzi P; Yang Z; Wu N; Liangpunsakul S; Alpini G; Francis H
    Biochim Biophys Acta Mol Basis Dis; 2019 Dec; 1865(12):165557. PubMed ID: 31521820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient Kit
    Hargrove L; Kennedy L; Demieville J; Jones H; Meng F; DeMorrow S; Karstens W; Madeka T; Greene J; Francis H
    Hepatology; 2017 Jun; 65(6):1991-2004. PubMed ID: 28120369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.
    Meadows V; Kennedy L; Ekser B; Kyritsi K; Kundu D; Zhou T; Chen L; Pham L; Wu N; Demieville J; Hargrove L; Glaser S; Alpini G; Francis H
    Hepatology; 2021 Nov; 74(5):2684-2698. PubMed ID: 34164827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling.
    Zhou T; Meadows V; Kundu D; Kyritsi K; Owen T; Ceci L; Carpino G; Onori P; Gaudio E; Wu N; Glaser S; Ekser B; Alpini G; Kennedy L; Francis H
    Hepatol Commun; 2022 Oct; 6(10):2715-2731. PubMed ID: 35799467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents.
    Kennedy LL; Hargrove LA; Graf AB; Francis TC; Hodges KM; Nguyen QP; Ueno Y; Greene JF; Meng F; Huynh VD; Francis HL
    Lab Invest; 2014 Dec; 94(12):1406-18. PubMed ID: 25365204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment.
    Kennedy L; Meadows V; Kyritsi K; Pham L; Kundu D; Kulkarni R; Cerritos K; Demieville J; Hargrove L; Glaser S; Zhou T; Jaeger V; Alpini G; Francis H
    Am J Pathol; 2020 May; 190(5):1018-1029. PubMed ID: 32142732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Kyritsi K; Kennedy L; Meadows V; Hargrove L; Demieville J; Pham L; Sybenga A; Kundu D; Cerritos K; Meng F; Alpini G; Francis H
    Hepatology; 2021 Jun; 73(6):2397-2410. PubMed ID: 32761972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2
    Kyritsi K; Francis H; Zhou T; Ceci L; Wu N; Yang Z; Meng F; Chen L; Baiocchi L; Kundu D; Kennedy L; Liangpunsakul S; Wu C; Glaser S; Alpini G
    Gene Expr; 2020 Nov; 20(2):89-103. PubMed ID: 32393417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling.
    Kennedy L; Meadows V; Demieville J; Hargrove L; Virani S; Glaser S; Zhou T; Rinehart E; Jaeger V; Kyritsi K; Pham L; Alpini G; Francis H
    Lab Invest; 2020 Jun; 100(6):837-848. PubMed ID: 32054995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
    Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
    Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2
    O'Brien A; Zhou T; White T; Medford A; Chen L; Kyritsi K; Wu N; Childs J; Stiles D; Ceci L; Chakraborty S; Ekser B; Baiocchi L; Carpino G; Gaudio E; Wu C; Kennedy L; Francis H; Alpini G; Glaser S
    Hepatol Commun; 2022 Jul; 6(7):1574-1588. PubMed ID: 35271760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
    van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
    Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of hepatic mast cells from cholestatic rats.
    Hargrove L; Graf-Eaton A; Kennedy L; Demieville J; Owens J; Hodges K; Ladd B; Francis H
    Lab Invest; 2016 Nov; 96(11):1198-1210. PubMed ID: 27548803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
    Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
    FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.